F
FlowCardia
FlowCardia designs and develops catheter-based technologies for the treatment of totally occluded coronary and peripheral arteries
About FlowCardia
FlowCardia, Inc. operated as a medical device company, established in 2002 and based in Sunnyvale, California. The company focused on developing and manufacturing endovascular devices designed to treat chronic total occlusions (CTOs), which are complete blockages of coronary and peripheral arteries. Its target clients were interventional cardiologists, vascular surgeons, and interventional radiologists who perform procedures to restore blood flow in patients with blocked arteries, often in the legs. The business model centered on the sale of its specialized catheter systems and related products to healthcare facilities.
Read full description
FlowCardia's flagship product was the CROSSER® CTO Recanalization Catheter System. This minimally-invasive device utilized high-frequency, mechanical vibrations to create a path through hard-to-penetrate arterial blockages, enabling physicians to then use other treatments like balloon angioplasty or stenting. The product portfolio included several models of the CROSSER Catheter, such as the 14P, 14S, and 18, tailored for different vessel sizes and locations. The company also developed complementary products like the FlowMate™ Injector, which simplified the procedure by integrating system controls into a single foot pedal for the physician.
A significant milestone for the company was receiving FDA 510(k) clearance for its peripheral CROSSER catheters, enabling their launch in the U.S. market. Throughout its history, FlowCardia raised over $42 million in venture capital funding from investors including Gilde Healthcare Partners, Frazier Healthcare Ventures, and JPMorgan Partners. In May 2010, the company was acquired by C. R. Bard, Inc. (now part of Becton, Dickinson and Company) for approximately $80 million, marking its successful exit.
At a glance
- Status
- Acquired
- Founded
- 2002
- Headquarters
- Sunnyvale, United States
- Open positions
- None listed
- Dealroom signal
- 19.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Cardiology and cardiovascular, Patient Care, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning FlowCardia.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2010 | $80M | $80M | C. R. Bard | — |
| SERIES C✓Equity / VC | Aug 2007 | $30M | $120M | Gilde Healthcare | — |
Growth signals
Latest recorded traffic for FlowCardia is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Frazier Healthcare Partners
Series B and later1 investor entered at this stage
Gilde Healthcare
Other known investors2 additional known investors
- CBC. R. Bard
Pappas Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about FlowCardia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See FlowCardia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.